Level Zero Health

Market position

The company presents itself as creating a new product category for hormone measurement, explicitly analogising to how continuous glucose monitors created a large market for diabetes management. It was covered by Forbes in a February 2026 piece on who is winning continuous hormone monitoring. Tech.eu described its £5.5 million round as the largest pre-seed raised by a female-founded company in Europe. Investor listings place it alongside other hormone and metabolic monitoring companies such as Eli Health and Levels Health.

Differentiation claims centre on direct measurement of the hormone itself from interstitial fluid rather than proxy signals or inference, use of aptamers instead of enzyme-based sensing (allowing a wider range of hormone targets and avoiding animal-derived materials), minimally invasive wearable form factor requiring little user action, results in minutes without a laboratory or phlebotomist, and data correlated with blood readings.

Technology

The core technology is aptamer-based (DNA-based) electrochemical/optical sensing. Aptamers are chemically synthesised single-stranded DNA molecules that bind specific hormone targets and fold measurably on binding, which the company contrasts with the enzyme-based chemistry used in continuous glucose monitors that does not translate to hormones. Sensing is performed on interstitial fluid accessed through microneedles in a skin-worn patch, avoiding the 10-20 hour lag the founders attribute to urine-based testing. An initial device version generates a colourimetric reaction read by a camera. Supporting capabilities on the team include electrochemical and microfluidic biosensing, MEMS and microfluidic platforms, nanoparticle functionalisation and bioconjugation, and LC-MS bioanalytical assay validation.

Go-to-market

The company plans to enter the market first with a single-use, intermittent-measurement patch that fits existing clinical protocols (compared by the CEO to finger-stick devices), targeting prescription use in fertility (IVF) and low-testosterone/TRT settings, before introducing continuous monitoring. It is recruiting a select group of research institutions and clinical partners via a proposals process covering IVF monitoring, perimenopause and menopause, hypogonadism and TRT management, fundamental hormone biology, intervention studies and clinical trials where sampling frequency has been limiting. Regulatory pathways pursued include FDA clearance and CE marking.

Healthcare provider networks, clinical organisations and research institutions; end-use cases include IVF patients, people going through perimenopause and menopause, and men with hypogonadism or on testosterone replacement therapy. The company notes that monitoring male hormones is a core part of its initial business plan alongside women's health.

Geography

Sources place the company variously in the UK — a London office at 20 Water Street, Wood Wharf, E14 5GX, and description as a UK startup — and in the US, with HAX listing Newark, NJ and United Kingdom, and MassDevice describing it as San Francisco-based. Team members have worked across the UK, Singapore and Hong Kong. Regulatory ambitions cover both the US (FDA) and Europe (CE marking).

History

The company was reported in February 2025 to be a little over a year old. It participated in the HAX 2024 cohort (SOSV) and presented onstage at TechCrunch Disrupt as part of the Startup Battlefield competition in autumn 2024. In February 2025 it announced an oversubscribed pre-seed round of $6.9 million (reported as £5.5 million by European outlets), led by Redalpine with participation from HAX (SOSV), Entrepreneur First and industry experts, with proceeds earmarked for R&D and team expansion. By the time of its partner-facing 'Collaborate' page, the company stated it had shown clinical-grade hormone measurement without a blood draw was possible and had opened proposals to research and clinical partners.

Risks & controversies

The sources note execution risks inherent to hardware and medical devices: the company acknowledges a paradigm shift in hormone monitoring cannot be delivered quickly, requires clinical trials and regulatory clearance (FDA and CE) before commercial sale, and must demonstrate sufficient correlation with blood-draw measurements — a target stated as 90%+ but not yet achieved at the time of reporting. Interstitial fluid readings lag blood-based readings, though the CEO argues the medical risk profile of hormone monitoring is lower than for glucose monitoring. Validation reported to date was in simulated samples rather than human clinical use, and the company states its current partner programme is not a commercial launch. Public sources also give inconsistent headquarters locations.